In the Spring of 2015, greenhouse tomato plants grown in Jordan presented with a mosaic pattern of light and dark green patches on leaves, narrowing leaves, and yellow- and brown-spotted fruit (Salem et al. 2015). The pathogen was identified as a novel plant virus, the tomato brown rugose fruit virus (ToBRFV), and the original outbreak was traced back to the fall of 2014 to Israel (Luria et al. 2017). This newly emerging virus can infect tomato and pepper plants at any stage of development and greatly affect crop yield and quality. Furthermore, the virus spreads rapidly by mechanical contact but can also be spread over long distances by contaminated seeds (Caruso et al. 2022), and as of 2022 it had been detected in 35 countries across four continents (Zhang et al. 2022). Compounding its transmissibility, is the ability of the virus escape plant genetic resistance to viral infection (Zhang et al. 2022). There are seven host plants for the virus, including some common grasses and weeds, which could act as a reservoir for the virus, even if it is eliminated from commercial crops. Some researchers consider ToBRFV to be the most serious threat to tomato production in the world.
Continue reading “Automated Sampling and Detection of ToBRFV: An Emerging Tomato Virus “Employee-Led Program Reduces Landfill Waste by Rescuing Plastic Film
Katelyn Geleynse presses the button and the machine groans to life. The massive metal plates shift until a half-ton of compressed plastic tumbles out onto the waiting pallet. The crowd cheers. Permanent markers are passed around and everyone takes turns signing the massive block.
It’s February 16, 2024, and the members of the Promega Sustainability Committee are gathered to witness the first bale of plastic film being ejected from the Madison campus’s new baler. It’s only the first bale, but it represents a major step in the company’s efforts to reduce plastic waste.
“All of this would have gone to the landfill if we hadn’t set up this program,” Katelyn says. “It feels good to know that at least some of my waste is getting a second life.”
Plastic film is notoriously difficult to recycle and takes decades to break down in a landfill. The Promega initiative to divert this waste was started by a small group of employees who noticed a problem and worked for over a year to build a sustainable solution. What began as a small volunteer operation grew to spur capital investment in a process that will rescue around 35,000 pounds of plastic per year.
Continue reading “Employee-Led Program Reduces Landfill Waste by Rescuing Plastic Film”Rooted in Resilience: The Future of Pest-Resistant Crops
Farmers everywhere strive to protect their crops and ensure a stable food supply while minimizing environmental harm. A promising approach to achieving this leverages a plant’s built-in defense mechanisms, reducing the need for chemical interventions. Many geneticists and agronomists lean on technologies that can automate and streamline nucleic acid extraction and pathogen detection to identify naturally pest resistant crops and, ultimately, keep up with the changing agricultural landscape.
Continue reading “Rooted in Resilience: The Future of Pest-Resistant Crops”Decades of Discovery: How the NCI-60 Revolutionized Cancer Drug Screening
The National Cancer Institute’s NCI-60 drug screening panel, comprised of 60 diverse human cancer cell lines, has been a cornerstone in advancing cancer research and drug discovery since its inception in the late 1980s. Developed in response to the need for more predictive and comprehensive preclinical models, the NCI-60 facilitates the screening of thousands of compounds annually, aiming to identify potential anti-cancer drugs across a broad spectrum of human cancers. This article traces the origins, development, and evolution of the NCI-60 panel, highlighting its significant role in advancing our understanding of cancer and therapeutic agents.
Continue reading “Decades of Discovery: How the NCI-60 Revolutionized Cancer Drug Screening”Celebrating Our 2023 Promega In Action Awardees
Each year, Promega employees are offered the opportunity to receive up to 40 hours paid time off to donate in volunteer service through our Promega In Action program. Providing sustained support of organizations in our community, our employees participate in a wide range of activities.
In 2023, we awarded 26 individuals who volunteered for 23 different organizations, some bringing along their Promega team members in attendance. From crafting comfort shawls for families of future organ and tissue donors, to volunteering with Meals on Wheels, to journeying to South Africa to deliver charitable donations for children in need, the opportunities to contribute to our community are abundant and impactful.
Continue reading “Celebrating Our 2023 Promega In Action Awardees”Studying Episodic Memory through Food-Caching Behavior in Birds
Your ability to navigate space and time is anchored in your memory, particularly episodic memory, which catalogues the experiences you have in a given location. This type of memory is shaped by complex neural networks firing within your hippocampus. So how exactly do we store memories of the hundreds of things that happen to us in a day, especially when they unfold in the same settings?
There are theories as to how we form single-shot, or “episodic”, memories, many of which center around the activity of place cells, which light up when you are in a specific environment. The idea here is that, with every event that happens in a place, these cells would shift and fire in novel patterns. Scientists at the Zuckerman Mind Brain Behavior Institute at Columbia University questioned this—while it is known that place cell activity can certainly be affected by experiences, they wondered whether there could be an alternative explanation for episodic recall that wouldn’t require the constant remapping of one’s core memory of a place.
Continue reading “Studying Episodic Memory through Food-Caching Behavior in Birds”AI in the Research Lab: Where We Are, and Where We’re Going
This guest blog post is written by Poncho Meisenheimer, Vice President of Research and Development.
I got into an argument with ChatGPT this morning.
That’s not unusual. I argue with ChatGPT a lot. In fact, that’s usually my goal.
As a scientist and a leader, it’s important to pressure-test my ideas. I need to account for biases, identify limitations, and strengthen weak points. Large language models like ChatGPT have given me a powerful tool in my pocket to become a better version of myself.
The advent of generative artificial intelligence has changed our world. We can’t keep doing things the way we did even only a year ago.
Promega is embracing AI. Every department is finding groundbreaking and responsible ways to deepen their impact using our ChatGPT enterprise license. As the Vice President of Research and Development, I have been working with our scientists to think beyond simple queries and imagine new horizons we can explore with these tools.
Make no mistake: I don’t think that ChatGPT and other AI tools can, will or should replace human scientists. Instead, they will empower all scientists to ask more ambitious questions and uncover new answers. They will upend our current paradigm about what science is and how it operates, and will help us build an even deeper understanding of the world around us.
Continue reading “AI in the Research Lab: Where We Are, and Where We’re Going”Silencing the Immunogenicity of AAV Vectors
Recombinant adeno-associated viral (AAV) vectors are an appealing delivery strategy for in vivo gene therapy but face a formidable challenge: avoiding detection by an ever-watchful immune system (1,2). Efforts to compensate for the immune response to these virus particles have included immunosuppressive drugs and engineering the AAV vector to be especially potent to minimize its effective dosage. These methods, however, come with their own challenges and do not directly solve for the propensity of AAV vectors to induce immune responses.
A recent study introduced a new approach to reduce the inherent immunogenicity of AAV vectors (2). Researchers strategically swapped out amino acids in the AAV capsid to remove the specific sequences recognized by T-cells that elicit the most pronounced immune response. As a result, they significantly reduced T-cell mediated immunogenicity and toxicity of the AAV vector without compromising its performance.
Read on to get more of the study details, which include the use of NanoLuc® luciferase and Nano-Glo® Fluorofurimazine In Vivo Substrate for in vivo bioluminescent imaging of the AAV variants’ distribution and transduction efficiency in mice.
Continue reading “Silencing the Immunogenicity of AAV Vectors “Discovery of Protein Involved in TDP-43 Cytoplasmic Re-Localization Points to Potential Gene Therapy for ALS and FTD
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are fatal and rapidly progress as neurodegenerative diseases. While inherited mutations can cause both conditions, they mostly appear sporadically in individuals without a known family history. Despite affecting different neurons, both diseases share a common hallmark: the pathogenic buildup of abnormal nuclear TAR-binding protein 43 (TDP-43) in the cytoplasm of affected motor neuron cells. Current theories propose that this cytoplasmic re-localization triggers toxic phosphorylation and fragmentation of TDP-43. Concurrently, a decrease of TDP-43 in the nucleus diminishes TDP-43-related physiological nuclear functions, contributing to the diseases’ progression (1).
Although this cytoplasmic accumulation of TDP-43 plays a significant role in the pathogenesis of ALS and FTD, the cellular mechanisms involved in the re-localization of TDP-43 to the cytoplasm is not known (2). A team of Australian neuroscientists led by Dr. Lars Ittner believe that they have found part of the answer for sporadic forms of the diseases. They identified novel interactions between pathogenic or dysfunctional forms of TDP-43 and the 14.3.3ɵ isoform of the cytoplasmic protein 14-3-3. By targeting this interaction with an AAV-based gene therapy vector, they were able to block and even partially reverse neurodegeneration in ALS/FTD mouse models.
Continue reading “Discovery of Protein Involved in TDP-43 Cytoplasmic Re-Localization Points to Potential Gene Therapy for ALS and FTD”Celebrating 10 Years of Innovation: Introducing the CSCB-Promega Innovation Fund
For the past decade, Promega has supported cutting-edge research through the CSCB-Promega Innovation Award. Now, as we mark 10 years of collaboration with the Chinese Society for Cell Biology (CSCB), the Award is being converted into the CSCB-Promega Innovation Fund.
The CSCB, founded in 1980, is one of the leading scientific organizations in China. Dedicated to fostering educational opportunities and innovation, the CSCB organizes conferences, publishes journals, promotes research collaborations, offers training for students and young scientists, and educates the general public on cell biology and biomedicine.
Continue reading “Celebrating 10 Years of Innovation: Introducing the CSCB-Promega Innovation Fund “